YHLO

Founded in 2008 and headquartered in Shenzhen, China, YHLO Biotech is a globally recognized innovator in in vitro diagnostics (IVD). With a deep commitment to scientific excellence and clinical impact, YHLO develops and delivers advanced immunoassay solutions powered by chemiluminescence, ELISA, immunoblot, and immunofluorescence technologies. Listed on the Shanghai Stock Exchange since 2021 (Stock Code: 688575), YHLO has built a strong foundation in R&D, partnering closely with leading universities, hospitals, and research institutions worldwide. Our expanding portfolio covers a wide range of disease areas, including fertility and reproductive health, autoimmune disorders, infectious diseases, diabetes, thyroid function, and rare disease detection. YHLO is certified by international standards including ISO 9001:2015, ISO 13485:2016, Korea KGMP, and Australia TGA, reflecting our unwavering dedication to quality. Today, YHLO’s solutions are trusted in nearly 100 countries, supported by a global network of partners and ongoing collaborations in Europe, the United States, Japan, and Australia. With a mission to create lasting value through diagnostic innovation, YHLO continues to advance healthcare—one test at a time.